RT Journal Article
SR Electronic
T1 Triplet Chemotherapy with Docetaxel, Gemcitabine and Liposomal Doxorubicin, Supported with Subcutaneous Amifostine and Hemopoietic Growth Factors, in Advanced Non-small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1427
OP 1431
VO 25
IS 2B
A1 PATLAKAS, GEORGE
A1 BOUROS, DEMOSTHENES
A1 TSANTEKIDOU-POZOVA, SOFIA
A1 KOUKOURAKIS, MICHAEL I.
YR 2005
UL http://ar.iiarjournals.org/content/25/2B/1427.abstract
AB The activity of a triplet of chemotherapeutic drugs, namely docetaxel, gemcitabine and liposomal doxorubicin, was investigated in patients with advanced non-small cell lung cancer. The regimen was supported with amifostine cytoprotection (1000mg injected subcutaneously) and hemopoietic growth factors (rhuG-CSF and rhuEPO) in an attempt to minimize the substantial toxicity reported in previous studies investigating docetaxel/gemcitabine chemotherapy. Twenty chemotherapy- naïve patients with advanced non-small cell lung cancer (NSCLC) (18 with stage IV and 2 with stage IIIb) were recruited. None of the patients presented with grade 3-4 hematological or non-hematological toxicity. Palmar-plantar erythrodysesthesia grade 2 was noted in 6/20 (30%), mucositis/oesophagitis grade 2 in 3/20 (15%) and mild alopecia in 6/20 (30%) patients. No case of interstitial pneumonia was noted. The overall response rate (complete and partial) in 18 evaluable patients was 33% (6/18), with 1/18 (5%) patients achieving complete response. The median survival was 11 months. The efficacy of the regimen was as high as the one reported in gemcitabine/docetaxel studies, but the toxicity was remarkably lower. Amifostine may have contributed to the better tolerance profile observed. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved